BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24966939)

  • 1. Prognostic value of Ki67 index in gastrointestinal stromal tumors.
    Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Lin TL; Shen YY; Liu Q; Cao H
    Int J Clin Exp Pathol; 2014; 7(5):2298-304. PubMed ID: 24966939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
    BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
    Li J; Gong JF; Wu AW; Shen L
    Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
    Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
    J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic analysis of gastrointestinal stromal tumors in duodenum and small intestine.
    Han IW; Jang JY; Lee KB; Kang MJ; Kwon W; Park JW; Chang YR; Lee HJ; Park KJ; Kim SW
    World J Surg; 2015 Apr; 39(4):1026-33. PubMed ID: 25270345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumor: 15-years' experience in a single center.
    Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
    BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
    Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
    Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal stromal tumors (GIST): a single center experience.
    Kostka R; Gürlich R; Koldová L
    Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
    Jiang J; Jin MS; Suo J; Wang YP; He L; Cao XY
    World J Gastroenterol; 2012 May; 18(20):2569-75. PubMed ID: 22654456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
    Li Y; Meng X
    Ann R Coll Surg Engl; 2015 Apr; 97(3):215-20. PubMed ID: 26263807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
    Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
    Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New fronts in the adjuvant treatment of GIST.
    Reichardt P; Joensuu H; Blay JY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in adjuvant therapy of gastrointestinal stromal tumors.
    Adekola K; Agulnik M
    Curr Oncol Rep; 2012 Aug; 14(4):327-32. PubMed ID: 22535506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.